Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THE WOODLANDS, Texas, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph Podolski, President and CEO of Repros, will present an update for the...
-
Vaginal delivery significantly improves risk:benefit ratio Company set to commence Phase 2 study early in 2012 and expects the trial will be completed in the same year o ...
-
Consistent induction of cessation of menses, the efficacy surrogate observed at daily doses as low as 3mg No evidence of liver enzyme elevations at any daily dose tested (maximum 12 mg)...
-
THE WOODLANDS, Texas, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the Company has hired Donald Tredway as its Chief Medical Officer. Dr. Tredway...
-
THE WOODLANDS, Texas, Dec. 27, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the Company has received the official FDA minutes from its recent Type C meeting...
-
THE WOODLANDS, Texas, Dec. 27, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a status update for the one year open label extension of its Phase 2 clinical study...
-
Statistically significant and clinically relevant improvement in testosterone production observed versus placebo and equivalent to an approved topical testosterone product Androxal®...
-
THE WOODLANDS, Texas, Dec. 14, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a regulatory update for its Androxal program following a joint meeting with the...
-
Statistically significant and clinically relevant improvement in testosterone production observed Androxal® exhibited dose dependent trends in improvement of indices of gylcemic...
-
THE WOODLANDS, Texas, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has been selected to present the Company's technologies at the 6th Annual...